Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of Wilms' tumor~  * Eligible subtypes:~    * Favorable histologies~   * Anaplastic histologies~   * Clear cell sarcoma of the kidney~   * Rhabdoid tumor of the kidney~* Relapsed disease after entry on protocol NWTS-5 (NWTS-Q9401)~PATIENT CHARACTERISTICS:~Age:~* 21 and under at original diagnosis~Performance status:~* Not specified~Life expectancy:~* At least 4 weeks~Hematopoietic:~* Absolute neutrophil count at least 1,000/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 1.5 times normal~* SGOT or SGPT less than 2.5 times normal~Renal:~* Creatinine no greater than 1.5 times normal OR~* Creatinine clearance or GFR at least 70 mL/min~Cardiovascular:~* Shortening fraction at least 27% by echocardiogram OR~* Ejection fraction greater than 50% by echocardiogram or MUGA scan~Other:~* Not pregnant~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* At least 2 weeks since prior chemotherapy and recovered~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* No prior therapy for relapsed Wilms' tumor~* Recovered from the toxic effects of any other prior therapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- STRATUM A (Type: EXPERIMENTAL): Treatment of children in Stratum A will be determined by the site of relapse and the presence of microscopic or gross residual disease after attempted surgical excision of the relapse.
- Stratum B (Type: EXPERIMENTAL): All children who received combination chemotherapy with Regimen EE - 4A as their initial therapy for Wilms tumor will receive Regimen I and radiation therapy to the site of recurrence. All patients will receive prophylactic trimethoprim /sulfamethoxazole
- STRATUM C (Type: EXPERIMENTAL): All children who received combination chemotherapy with Regimen DD - 4A as their initial therapy for Wilms tumor will be treated with the following chemotherapy. All patients will receive prophylactic trimethoprim/sulfamethoxazole
- STRATUM D (Type: EXPERIMENTAL): Six week cycles of chemotherapy will be given to all patients who do not have progressive disease at the time of each week 0 re-evaluation.

Based on this trial design, predict the completion outcome and termination type (if applicable).